Is Mirtazapine a Tricyclic or Tetracyclic Drug?

Mirtazapine is a tetracyclic antidepressant, not a tricyclic. Its chemical structure contains four fused rings rather than the three rings that define the tricyclic class, and its pharmacology differs from tricyclics in ways that matter far more than the ring count alone. Mirtazapine is more precisely classified as a noradrenergic and specific serotonergic antidepressant, or NaSSA, a label that actually describes how it works rather than just what shape its molecule takes.¹ The confusion between the two classes is understandable, though, because mirtazapine was developed from an older tetracyclic drug and the two categories share some surface-level similarities that fall apart on closer inspection.

What “Tricyclic” and “Tetracyclic” Actually Mean

These terms refer to the core chemical skeleton of the drug molecule. Tricyclic antidepressants like amitriptyline and imipramine have a backbone of three interconnected rings, typically two benzene rings joined by a seven-membered central ring. Tetracyclic antidepressants add a fourth ring to this arrangement. In mirtazapine’s case, the four-ring structure includes a piperazine ring fused to the three-ring system, and a nitrogen atom in the central ring where its predecessor, mianserin, has a carbon atom.

The ring count started out as a convenient naming shorthand decades ago, when the first tricyclic antidepressants were discovered and the most obvious thing they had in common was that three-ring backbone. As more antidepressants were developed, some with four rings, the naming convention simply extended. But the label was always about molecular shape, not about how the drugs actually affect the brain. Two tetracyclic drugs can work through completely different mechanisms, just as two tricyclic drugs can have substantially different receptor profiles from each other. This is why most modern references prefer functional classifications over structural ones.

How Mirtazapine Works Differently from Tricyclics

The single biggest pharmacological difference between mirtazapine and the tricyclic class is that mirtazapine does not block the reuptake of serotonin or norepinephrine. Tricyclics are, at their core, reuptake inhibitors. They work by physically plugging the transporter proteins that suck serotonin and norepinephrine back into the nerve cell after they have been released. This keeps more of those neurotransmitters floating in the synapse, which is how they produce their antidepressant effect. The problem is that tricyclics also block a grab bag of other receptors along the way, which is where many of their side effects come from.

Mirtazapine takes an entirely different approach. Instead of blocking reuptake, it acts as an antagonist at alpha-2 adrenergic receptors, which are regulatory receptors that normally act as a brake on neurotransmitter release.² By blocking these brakes, mirtazapine causes nerve cells to release more norepinephrine and serotonin. It enhances serotonergic activity further by blocking certain serotonin receptors (specifically the 5-HT2 and 5-HT3 subtypes) while leaving the 5-HT1A receptor pathway intact, which channels serotonin’s effects through pathways associated with mood improvement rather than the pathways linked to nausea or sexual dysfunction.³ Research has confirmed that mirtazapine is not a serotonin reuptake inhibitor, and its effects on serotonin transporters appear to operate through a more complex, indirect mechanism.⁴

This distinction is not just academic. The absence of reuptake inhibition means mirtazapine lacks many of the side effects most commonly associated with both tricyclics and SSRIs, particularly sexual dysfunction, which is one of the leading reasons patients stop taking other antidepressants. It also means mirtazapine does not carry the same risk of serotonin syndrome when combined with other drugs, though caution is still warranted in combination therapy.

Why “NaSSA” Is a More Useful Label

The classification that best captures what mirtazapine actually does is NaSSA, for noradrenergic and specific serotonergic antidepressant.⁵ This term was coined specifically for mirtazapine because none of the existing categories fit. It is not an SSRI (it does not inhibit serotonin reuptake), not an SNRI (it does not inhibit norepinephrine reuptake either), not a tricyclic (wrong structure and wrong mechanism), and calling it simply “tetracyclic” groups it with drugs like mianserin and maprotiline that work differently from it. NaSSA captures the two key features: it boosts noradrenergic activity and it selectively channels serotonergic activity through specific receptor subtypes rather than flooding all serotonin pathways indiscriminately.

In practice, you will see mirtazapine referred to as a tetracyclic in older references and drug databases, and as a NaSSA in newer clinical literature. Both are technically correct, but the NaSSA label tells you something useful about what to expect from the drug, while “tetracyclic” tells you only what the molecule looks like under a microscope. Many pharmacologists and psychiatrists now consider the structural classification system outdated, precisely because two drugs can share a ring count while having completely different clinical profiles, side effects, and drug interactions.

Mirtazapine’s Relationship to Mianserin

Mirtazapine was designed as a deliberate modification of mianserin, an earlier tetracyclic antidepressant developed in the 1970s. The key structural change was swapping a single carbon atom in mianserin’s central ring for a nitrogen atom, a modification chemists call isosteric replacement. This seemingly minor tweak had outsized effects on the drug’s properties.⁶

Compared to mianserin, mirtazapine has a much weaker affinity for alpha-1 adrenergic receptors and essentially no norepinephrine reuptake activity. The alpha-1 receptor is the one responsible for orthostatic hypotension, that dizzy feeling when you stand up too fast, which was a significant problem with mianserin and remains a hallmark side effect of many tricyclics. Mirtazapine’s reduced alpha-1 binding translates directly to a lower risk of this particular side effect. The nitrogen substitution also changed how the drug is metabolized in the liver, giving mirtazapine a cleaner pharmacokinetic profile and fewer problematic drug interactions than its predecessor.

Mianserin had another clinical liability: it was associated with a rare but serious risk of agranulocytosis, a dangerous drop in white blood cells. While mirtazapine carries a theoretical risk as well, the incidence is much lower, and routine blood monitoring is not generally required. Understanding that mirtazapine is a refined descendant of mianserin, not a modified tricyclic, helps explain why it behaves the way it does.

The Sedation and Weight Gain Trade-Off

If mirtazapine sidesteps many of the classic tricyclic side effects, it has a signature side-effect profile of its own: sedation and weight gain. These are driven largely by its potent antagonism of histamine H1 receptors. A brain-imaging study in healthy volunteers found that mirtazapine occupied roughly 80 to 90 percent of histamine H1 receptors in the cerebral cortex, and that the degree of occupancy correlated with how sleepy people felt.⁷

This is actually where comparing mirtazapine to tricyclics gets interesting. Tricyclics also block histamine receptors, and sedation and weight gain are common complaints with drugs like amitriptyline. But mirtazapine’s sedation has a quirk that tricyclics generally do not share: it tends to be more pronounced at lower doses and can actually diminish as the dose increases. The reason is that at higher doses, mirtazapine’s noradrenergic effects ramp up enough to counterbalance the histamine-driven drowsiness. This means a patient who is too sedated on 15 milligrams may paradoxically feel more alert on 30 milligrams, a dose-response relationship that confuses patients and prescribers alike if they are not expecting it.

Tricyclics, by contrast, tend to produce more sedation at higher doses, not less, because their sedating properties scale linearly with their antihistamine and anticholinergic effects. This is one of several practical differences that make the tricyclic-versus-tetracyclic distinction more than a matter of molecular geometry.

Cardiovascular Safety Compared to Tricyclics

One of the most clinically important differences between mirtazapine and the tricyclic class is cardiac safety. Tricyclics are well known for their effects on the heart. They can slow cardiac conduction, prolong the QT interval, and in overdose, they are genuinely dangerous. Tricyclic overdose remains a serious cause of poisoning deaths, largely because of cardiac arrhythmias. This is one reason tricyclics fell out of favor as first-line treatments for depression once SSRIs became available in the late 1980s.

Mirtazapine’s cardiovascular profile is considerably cleaner. A large drug surveillance analysis spanning nearly two decades of data from German-speaking countries found that mirtazapine had a significantly lower rate of cardiovascular adverse reactions than all other antidepressant classes monitored. The rate was around 0.07 percent, and the risk of arrhythmia specifically was significantly lower than for other antidepressants.⁸ This makes mirtazapine a particularly attractive option for older adults or anyone with pre-existing cardiac concerns, populations where tricyclics would carry meaningful risk.

The reason for this difference comes back to mechanism. Tricyclics block sodium channels in cardiac tissue, which is what makes them dangerous to the heart. Mirtazapine does not have significant sodium channel activity. It also has very weak muscarinic anticholinergic effects,⁹ which means it largely avoids the dry mouth, constipation, urinary retention, and blurred vision that are classic anticholinergic side effects of tricyclics. For patients who have tried a tricyclic and found the side effects intolerable, mirtazapine often represents a genuinely different experience rather than more of the same.

The Enantiomer Question

Mirtazapine is prescribed as a racemic mixture, meaning it contains equal amounts of two mirror-image versions of the molecule, the (+) and (-) enantiomers. These are not interchangeable. Research in rats has shown that the two enantiomers have different neurochemical effects. The (-) enantiomer, for instance, produced a significant decrease in beta-1 adrenergic receptor affinity that the (+) enantiomer did not. Both enantiomers reduced serotonin 5-HT2 receptor density, but the racemic mixture appeared to be at least as effective as either enantiomer alone in altering the receptor populations thought to matter for antidepressant action.¹⁰

This finding has kept pharmaceutical development focused on the racemic mixture rather than pursuing a single-enantiomer version. Some other drugs have been commercially redeveloped as single enantiomers (the classic example being escitalopram, the active enantiomer of citalopram), but for mirtazapine, the evidence so far suggests that the two halves of the mixture complement each other rather than one carrying all the therapeutic weight. Whether a purified enantiomer could offer a cleaner side-effect profile without sacrificing efficacy remains an open question, but there has been no significant push to find out.

Mirtazapine in Veterinary Medicine

One area where mirtazapine has found an entirely separate life is in veterinary practice, particularly for cats. The drug’s appetite-stimulating side effect, the same property that causes weight gain in human patients, turns out to be therapeutically useful for cats with chronic kidney disease or cancer who are losing weight and refusing food.

A transdermal formulation, applied to the inner surface of the ear, has been developed specifically for feline use. Pharmacokinetic studies found that this transdermal ointment achieved measurable plasma concentrations in cats, with a bioavailability of about 65 percent compared to oral dosing.¹¹ In clinical trials, cats with chronic kidney disease who received compounded transdermal mirtazapine showed significant increases in weight, appetite, and rate of food consumption at both the higher and lower doses tested.¹²

A larger placebo-controlled trial confirmed these findings. Cats treated with 2 mg of transdermal mirtazapine daily gained an average of about 3.9 percent of their body weight over roughly two weeks, compared to just 0.4 percent in the placebo group.¹³ The treatment was well tolerated. This application is a good example of how a side effect that limits a drug’s usefulness in one context can become the primary therapeutic rationale in another. In feline medicine, mirtazapine is formally classified as a weight-gain drug rather than an antidepressant, a rebranding that would amuse anyone struggling with mirtazapine-related weight gain on the human side.

Why the Confusion Persists

Several factors keep the tricyclic-tetracyclic mix-up alive. First, both drug classes are older-generation antidepressants that predate the SSRI era, so they tend to get lumped together in informal conversation as “the old drugs.” Second, some electronic health records and pharmacy databases still categorize mirtazapine under “TCA/tetracyclic” as a combined heading, which implies more similarity than actually exists. Third, both classes can cause sedation and weight gain, so the clinical experience of taking them can feel overlapping even though the underlying pharmacology is quite different.

The confusion also matters practically. If a patient tells a new doctor that they “had a bad reaction to tricyclics,” and the doctor interprets that as including mirtazapine, the patient may be unnecessarily denied a drug that works through a fundamentally different mechanism and could be well tolerated. Conversely, a patient who did poorly on mirtazapine should not assume that tricyclics will produce the same problems, because the receptor profiles are distinct. Understanding that mirtazapine is pharmacologically its own thing, a tetracyclic by structure and a NaSSA by function, with a mechanism that has more in common with no other marketed antidepressant than with any specific class, is the most useful takeaway for navigating treatment decisions.